摘要
目的研究重组人生长激素在矮小症患儿治疗中的应用效果。方法从2015年2月～2017年1月某院收治的矮小症患儿中选取65例作为研究对象,按照数字表法将其分成对照组(32例)与研究组(33例)。两组均行常规治疗,研究组在该基础上行重组人生长激素治疗,对两组患儿骨龄、平均生长速率、成年身高预测值以及不良反应发生率进行比较。结果两组治疗前骨龄、平均生长速率和成年身高预测值比较,差异无统计学意义(P>0.05);治疗后,研究组骨龄、平均生长速率和成年身高预测值均明显优于对照组,差异有统计学意义(P<0.05);两组治疗后不良反应发生率比较,差异无统计学意义(P>0.05)。结论在矮小症患儿治疗上,重组人生长激素可有效增加患儿骨龄和成年身高预测值,提升其平均生长速率,且不良反应发生率低。
OBJECTIVE To study the effect of recombinant human growth hormone in the treatment of children with short stature. METHODS From February 2015 to January 2017,65 patients with short stature were selected and divided into the control group(32 cases) and the study group (33 cases) according to the digital table method. Routine treatment was performed in both groups. The study group was treated with recombinant human growth hormone therapy. The bone age,average growth rate,adult height prediction and incidence of adverse reactions were compared between the two groups. RESULTS There was no significant difference in the pre-treatment bone age,average growth rate and adult height prediction between the two groups (P>0.05). After treatment,the bone age,average growth rate and adult height prediction of the study group were significantly better than the control group (P<0.05). The incidence of adverse reactions after treatment in the two groups was not statistically significant (P>0.05). CONCLUSION In the treatment of children with short stature,recombinant human growth hormone can effectively increase the bone age and adult height prediction,increase the average growth rate,with good safety profile.
作者
李长秀
庞金梅
李小红
刘培兰
黄妙巧
焦鹏涛
LI Changxiu;PANG Jinmei;LI Xiaohong;LIU Peilan;HUANG Miaoqiao;JIAO Pengtao(Department of Children Healthcare,Zhanjiang City Maternal and Child Health Hospital,Zhanjiang,Guangdong 524038,China)
出处
《今日药学》
CAS
2018年第12期832-834,共3页
Pharmacy Today
关键词
矮小症患儿
重组人生长激素
疗效
安全性
children with short stature
recombinant human growth hormone
efficacy
safety
